Luigi Naldini, M.D., Ph.D, is the Director of the San Raffaele Telethon Institute of Gene Therapy and Professor of Tissue Biology and Gene and Cell Therapy at the San Raffaele University Medical School, Milan (Italy). Past President of the European Society of Gene and Cell Therapy (ESGCT), Member of EMBO, the European Molecular Biology Organization, has received several awards, including the Outstanding Achievement Award from the American Society of Gene and Cell Therapy and from ESGCT, the van Beutler Award from the American Society of Hematology, and an honorary doctorate from Vrije University, Brussel. He has pioneered and contributed to the development and application of several technologies for gene transfer and gene therapy, including lentiviral vectors and targeted genome editing. Some of these technologies have become widely used tools in biomedical research and, upon recently entering clinical testing, are showing safety and efficacy for the treatment of severe inherited diseases and some types of cancer. Has published 247 scientific papers cited >32,000 times, and was appointed to the National Academy of Sciences, USA, Study Committee on Human Gene Editing and the Italian National Committee for Biosafety, Biotechnology and Life Sciences.
« Go Back